Formulation development outsourcing market research and analysis by services, formulation optimization, by dosage form, by application, by end user and region forecast 2030. Global Formulation Development Outsourcing Market is expected to register a CAGR of 8.10% during the assessment period, to reach USD 13.63 Billion by 2030.
The growing popularity of formulation production outsourcing is being fueled by biopharmaceutical companies forming partnerships with universities, Contract Research Organizations (CROs), and biotechnology startup companies to develop formulations for diseases including cancer. Furthermore, as a growing number of pharmaceutical and biopharmaceutical companies outsource their services, new markets for formulation production outsourcing companies have emerged.
The expiration of significant drug patents is one of the factors boosting the market for formulation production outsourcing. The demand for medications and medical equipment has increased as a result of the growing population, particularly in emerging economies. The world market is expanding, particularly in developing nations like China and India. In the global healthcare industry, particularly in the pharmaceutical sector, a significant patent cliff is approaching. The patent cliff will make generic copies more accessible and raise demand for CMOs. The industry that is driving market expansion, healthcare contract manufacturing, is anticipated to profit from the rise in demand.
Additionally, the market is expanding as a result of the pharmaceutical industry’s rising need for outsourcing services, as well as the participation of market participants involved in new services and strategic partnerships. However, structural changes in the pharmaceutical industry and a lack of funding to complete the medication development process by outsourcing formulation development in developing nations are stifling demand growth.
The prominent players in the global formulation development outsourcing market are Laboratory Corporation of America (US), Charles River Laboratories (US), Catalent, Inc. (US), and Intertek (US).
Some of the significant strategies followed by players operating in the global formulation development outsourcing market were FDA approvals, joint ventures, expansions, acquisitions, and collaborations.
The global formulation development outsourcing market report is segmented based on services, dosage form, application, and end user.
The global market based on the services has been divided into preformulation services and formulation optimization.
The global formulation development outsourcing market, based on dosage form, has been segmented into injectable, topical, oral, inhaled, and others.
The global formulation development outsourcing market, based on application, is segmented into oncology, genetic disorders, neurology, infectious diseases, respiratory, cardiovascular, and others. Because of the increasing incidence of cancer and pharmaceutical companies’ active involvement in outsourcing their services, the oncology segment was the largest and fastest growing.
Pharmaceutical and biopharmaceutical firms, government agencies, and research institutes make up the global formulation production outsourcing sector, based on end-users. Because of the increasing demand for outsourcing pharmaceutical formulation production and outsourcing among drug developers, pharmaceutical and biopharmaceutical companies were a larger and faster-growing market.
The global formulation development outsourcing market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas are divided into two regions: North America and Latin America, with North America further divided into the United States and Canada. The Americas led the market in 2019 and are expected to continue to do so during the evaluation period. This is due to a well-established healthcare system, as well as the increasing prevalence of chronic diseases and the need for drug growth.
The market for embolization particles in Europe is divided into two parts: Western Europe and Eastern Europe. Germany, France, the United Kingdom, Italy, Spain, and the Rest of Western Europe make up the Western Europe formulation production outsourcing market. Due to the existence of favorable government policies, a broad target population base, rising prevalence of chronic and lifestyle-related disorders, and the acceptance of formulation production outsourcing by pharmaceutical and biopharma firms, Europe will trail the Americas in terms of value during the forecast era.
China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific make up the Asia-Pacific formulation production outsourcing industry. Due to the per capita health spending, the expanding healthcare sector in China, India, and Australia, growing demand for the drug development process, and a growing number of pharmaceutical companies engaged in drug development, Asia-Pacific is expected to have the highest market growth potential over the forecast period.
The demand for formulation development outsourcing in the Middle East and Africa is divided into two parts: the Middle East and Africa. The market growth in this area is expected to be driven by the gradual adoption rate of formulation production outsourcing.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)